AV-412_451493-31-5_DataSheet_MedChemExpress

OTC国际认证技术中心，欢迎前来咨询！欧洲CE认证尼日利亚SONCAP 沙特SASO 肯尼亚PVOC 坦桑尼亚COC 阿尔及利亚COC 赞比亚PVOC 墨西哥NOM 乌拉圭LATU 印度BIS 国际体育澳标AS 美标ASTM致敏染料/致癌染料测试：Allergenous disperse dyes 致敏性分散染料 HPLC-MS , DIN 54231Carcinogen dyes 致癌染料 HPLC-MS , DIN 54231常见含有致敏染料产品- 聚酯纤维、聚酰胺纤维及醋酸纤维的染色处理- 由于分散染料的分子量很低，经常用于涤纶转移印花- 色牢度比较差的尼龙织物- 目前容易出现致敏染料超标的产品有：? 长筒袜? 护腿? 短袜? 紧身衣? 罩衫和内衣一、致敏性分散染料Allergenous disperse致敏染料是指某些会引起人体或动物的皮肤、黏膜或呼吸道过敏的染料。

人体吸入性的过敏主要集中于呼吸道和粘膜，部分活性染料（可分为颗粒状和液状）可造成此类致敏。

目前致敏染料共发现27种。

在国际知名生态安全规范Oeko-Tex Standard 100的2008版中，将其中的20种致敏性分散染料列为生态纺织品的监控项目，下表中1#~20#，并增加了另外两种致敏染料，21#和22#。

这些染料主要用于聚酯、聚酰胺和醋酯纤维的染色，其中的17种为早期用于醋酸纤维的分散染料。

欧盟于2002年5月推出的Eco-Label标签标准规定：该标准所列出的17种染料（比Oeko-Tex Standard 100少了3种：C.I. 分散蓝1、C.I. 分散棕1和C.I. 分散黄3），并规定当染色纺织品的耐汗渍色牢度（酸性和碱性）低于4级时，不得使用。

禁用的致敏染料编号染料英文名称染料中文名称 CAS No.1#Disperse Blue 1 分散蓝1 2475-45-82# Disperse Blue 3 分散蓝3 2475-46-93# Disperse Blue 7 分散蓝7 3179-90-64# Disperse Blue 26 分散蓝26 3860-63-75# Disperse Blue 35 分散蓝35 12222-75-26# Disperse Blue 102 分散蓝102 69766-79-67# Disperse Blue 106 分散蓝106 12223-01-78# Disperse Blue 124 分散蓝124 61951-51-79# Disperse Brown 1 分散棕1 23355-64-810# Disperse Orange 1 分散橙 1 2581-69-311# Disperse Orange 3 分散橙3 730-40-512# Disperse Orange 37/76 分散橙37/76 13301-61-613# Disperse Red 1 分散红1 2872-52-814# Disperse Red 11 分散红11 2872-48-215# Disperse Red 17 分散红17 3179-89-316# Disperse Yellow 1 分散黄1 119-15-317# Disperse Yellow 3 分散黄3 2832-40-818# Disperse Yellow 9 分散黄 9 6373-73-519# Disperse Yellow 39 分散黄39 12236-29-220# Disperse Yellow 49 分散黄49 54824-37-221# Disperse Yellow 23 分散黄23 6250-23-322# Disperse Orange 149 分散橙149 85136-74- 9国际上目前对纺织品上限用致敏性分散染料检出的限定值，不同的买家所制订的合格性评定标准存在一些差异。

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :AV-412 (free base)Catalog No. :HY-10346ACAS No. :451492-95-81.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:MP⁻412 free base; AV412 free base; AV 412 free base; MP412 free base; MP 412 free base Formula:C27H28ClFN6OMolecular Weight:507.00CAS No. :451492-95-84. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

Datasheet for A549/Cas9AAVS1Cell LineCatalog number:SL504(SCL-76321-G2)Product:A549cell line stably expressing CRISPR Cas9nucleaseDescription:This product is a cell line stably expressing the CRISPR Cas9nuclease.Cas9is integrated at the human AAVS1Safe Harbor locus(also known as PPP1R2C).Thiscell line also expresses copGFP and the hygromycin resistance gene.Incombination with separately transfected or transduced single guide RNAs(sgRNAs),this cell line will sustain double-strand DNA breaks(DSBs)at targetedgenome sites.This cell line can be used in vitro for gene knockout,transgeneknockin,mutagenesis,transgene integration,or other genome editing-relatedapplications.Quantity:1vial of2x106cells;frozenShipping conditions:Dry iceStorage conditions:Liquid nitrogen vapor phase.Remove the item from the dry ice packaging and check all items for damage and leakage.Place immediately into storage at orbelow-1400C,preferably into the liquid nitrogen vapor phase,until use. Transgene integration:Source of parental line:A549Organism:Homo sapiens,humanTissue:Lung carcinomaCell type:EpithelialQuality control:>95%viability before freezing.All cells were tested and found to be free ofmycoplasma,bacterial,viruses,and other toxins.Safety instructions:To ensure safety,protective gloves,clothing,and a face mask should be wornwhen handling frozen vials.Some leakage may occur into the vial during storage.The liquid nitrogen will be converted to gas upon thawing.Due to the nature ofnitrogen gas,pressure may build within the vial and possibly result in the vialexploding or losing its cap.This may cause flying debris.Thawing procedure:The vial of cells should be thawed in a370C water bath with gentle agitation.For optimal performance,the vial should be thawed in under two minutes.Ensurethat the cap of the vial did not loosen upon thawing,and re-tighten as needed.Spray the vial with70%EtOH and wipe ing aseptic technique,addthe contents of the vial to9ml of complete growth medium(without selection).Centrifuge for5min.at125x g.Aspirate the medium,being careful not todisturb the pellet.Resuspend in10mL of complete growth medium,and placeinto a culture vessel of your choice.Only add selection to the medium after24hours in culture.Culture conditions:Complete Growth MediumThe base medium for this cell line is F12Medium.For optimal growth andmaintenance of selection,add the following components to the base medium:fetal bovine serum to a final concentration of10%.SelectionHygromycin to a final concentration of800µg/mLCulture temperature:370C with5%CO2Subculture:Rinse the cells with PBS without cations,digest cells with0.25%(w/v)Trypsin-EDTA(0.53mM)solution and split at1:3to1:10ratio.Cryopreservation:Freeze slowly in complete growth medium supplemented with5%(v/v)DMSO. Mycoplasma:Negative(MycoAllert Mycoplasma Detection Kit from Lonza)1.T7Endonuclease I(T7E1)AssaysgRNA targeting to B2M gene was transduced into A549/CAS9AAVS1cell line by lenti-particals LPP-HCP000395-b-LvSG02.B2M gene was cut by CAS9expressed inside the cells and repaired through NHEJ with mutation.A669bp B2M gene fragment from PCR was then tested by T7E1Assay.The T7E1cleavage will results in two additional bands:one~291bp and the other~378bp.Mutation was generated for B2M gene by CAS9/CRISPR and NHEJ2.Junctional PCR(to confirm the Cas9gene integration into AAVS1site)(1)5'Junctional PCR(one primer from chromosomal outside of the5'homology arm region,the other primer from the Cas9-plasmid region)Junction-PCR5'F:ccggaactctgccctctaacJunction-PCR5'R:gcgtacttggcatatgatPredict product length：1100bp(2)3'Junctional PCR(one primer from chromosomal outside of the3'homology arm region,the other primer from the Cas9-plasmid region)Junction-PCR3'F:agctatctggtctcccttccJunction-PCR3'R:tcctgggataccccgaagagPredict product length：1250bpCitation of product:If use of this item results in a publication,please use this information: CRISPR Cas9stable A549cell line(SL504;GeneCopoeia,Inc.,Rockville,MD).Limited Use LicenseA limited use license is granted to the Buyer of the Product.The Product shall be used by the Buyer for internalresearch purposes only.The Product is expressly not designed,intended,or warranted for use in humans or for therapeutic or diagnostic use.The Product must not be resold,repackaged or modified for resale,or used tomanufacture commercial products without prior written consent from GeneCopoeia.This Product should be used in accordance with NIH guidelines developed for recombinant DNA and genetic e of any part of the Product constitutes acceptance of the above terms.Copyright©2018GeneCopoeia,Inc.C9SCL-DS-032018GeneCopoeia,Inc.9620Medical Center Drive,#101Rockville,MD20850USATel:301-762-0888;Fax:301-762-3888Email:***********************Web:。

Mechanisms:
Pathways:GPCR/G protein; Target:CCR5 Pathways:Microbiology; Target:CCR5
g y Biological Activity: Maraviroc (UK-427857; Selzentry; Celsentri) is a Selective CCR5 antagonist; displays potent antiHIV-1 activity. Maraviroc (UK-427857; Selzentry; Celsentri) prevents the interaction of HIV-1 gp120 and CCR5 (IC50 = 6.4 nM), inhibiting HIV-1 entry. Maraviroc also inhibits CCL3 (MIP-1α) binding to CCR5.
References: [1]. Dorr et al (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective smallmolecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob.Agents Chemother. 49 4721. [2]. [ ] Romero-Sánchez MC, Machmach K, Gonzalez-Serna A, Genebat M, Pulido I, García-García M, Alvarez-Ríos AI, Ferrando-Martinez S, Ruiz-Mateos E, Leal M.Effect of maraviroc on HIV-disease progression-related biomarkers.Antimicrob Agents Chemother. 2012 Sep 4. [3]. Lu Y, Hendrix CW, Bumpus NN.Cytochrome P450 3A5 Plays a Prominent Role in the Oxidative Metabolism of the Anti-HIV Drug Maraviroc.Drug Metab Dispos. 2012 Aug 24. [4]. Willig JH, Wilkins SA, Tamhane A, Nevin CR, Mugavero MJ, Raper JL, Napolitano LA, Saag MS.Maraviroc Observational Study: The Impact of Expanded Resistance Testing and Clinical Conside...